Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan.
Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan.
Nutrients. 2020 Sep 11;12(9):2769. doi: 10.3390/nu12092769.
(1) Aim: Non-alcoholic fatty liver disease (NAFLD) is a prevalent disease worldwide. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) bear anti-inflammatory action and can ameliorate hyperlipidemia. We wish to appraise the effects of n-3 PUFAs supplement on NAFLD. (2) Methods: We searched CENTRAL, Embase, and MEDLINE on 29 March 2020 for randomized control trials (RCTs) on the effects of n-3 PUFAs supplementation in treating NAFLD. The Cochrane Collaboration's tool was used to assess the risk of bias of included RCTs. (3) Results: We included 22 RCTs with 1366 participants. The risk of bias of included RCTs was generally low or unclear. n-3 PUFAs supplementation significantly reduced liver fat compared with placebo (pooled risk ratio 1.52; 95% confidence interval (CI) 1.09 to 2.13). n-3 PUFAs supplementation also significantly improved the levels of triglyceride, total cholesterol, high-density lipoprotein, and body-mass index, with pooled mean difference and 95% CI being -28.57 (-40.81 to -16.33), -7.82 (-14.86 to -0.79), 3.55 (1.38 to 5.73), and -0.46 (-0.84 to -0.08), respectively. (4) Conclusions: The current evidence supports the effects of n-3 PUFAs supplementation in improving fatty liver. n-3 PUFAs supplementation may also improve blood lipid levels and obesity.
（1）目的：非酒精性脂肪性肝病（NAFLD）是一种全球性的常见病。ω-3 多不饱和脂肪酸（n-3PUFAs）具有抗炎作用，可以改善高脂血症。我们希望评估 n-3PUFAs 补充剂对 NAFLD 的影响。
（2）方法：我们于 2020 年 3 月 29 日在 CENTRAL、Embase 和 MEDLINE 上搜索了关于 n-3PUFAs 补充剂治疗 NAFLD 效果的随机对照试验（RCTs）。我们使用 Cochrane 协作组的工具评估了纳入 RCTs 的偏倚风险。
（3）结果：我们纳入了 22 项 RCTs，共 1366 名参与者。纳入 RCTs 的偏倚风险总体较低或不明确。与安慰剂相比，n-3PUFAs 补充剂显著降低了肝脏脂肪（汇总风险比 1.52；95%置信区间（CI）1.09 至 2.13）。n-3PUFAs 补充剂还显著改善了甘油三酯、总胆固醇、高密度脂蛋白和体重指数的水平，汇总均数差值和 95%CI 分别为-28.57（-40.81 至-16.33）、-7.82（-14.86 至-0.79）、3.55（1.38 至 5.73）和-0.46（-0.84 至-0.08）。
（4）结论：目前的证据支持 n-3PUFAs 补充剂改善脂肪肝的作用。n-3PUFAs 补充剂还可能改善血脂水平和肥胖。
